Physician profile
Nathan Eric Wilds
NPI 1285869503
$19,345.31
in general payments reported to CMS, 2019-2025
34 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,852 · 2020: $5,910 · 2021: $338 · 2022: $672 · 2023: $4,575 · 2024: $424 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,006 · Food and Beverage: $1,600 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,006.23 |
| Food and Beverage | $1,600.11 |
| Travel and Lodging | $966.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,604.01 | 2019-2025 | Trelegy Ellipta, Nucala |
| Intuitive Surgical, INC. | $4,179.51 | 2022-2024 | Da Vinci Surgical System |
| Pulmonx Corporation | $997.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $439.01 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.99 | 2019-2025 | Ofev |
| Insmed, INC. | $176.54 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $162.95 | 2019-2023 | Yupelri |
| United Therapeutics Corporation | $144.32 | 2021-2025 | Tyvaso |
| Genzyme Corporation | $135.55 | 2022-2025 | |
| Inari Medical, INC. | $132.90 | 2019 | |
| Genentech USA, INC. | $112.84 | 2019-2025 | Xolair |
| Merck Sharp & Dohme LLC | $111.84 | 2019-2025 | Zerbaxa, Recarbrio |
| Electromed, INC. | $104.07 | 2024 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $99.55 | 2021-2025 | Glassia |
| Grifols USA, LLC | $98.00 | 2019-2024 | Prolastin-C Liquid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $87.59 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $77.06 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Harmony Biosciences LLC | $73.08 | 2021-2022 | |
| Verona Pharma, INC. | $51.58 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $50.32 | 2023-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $38.42 | 2019 | |
| Amgen INC. | $29.28 | 2024-2025 | Tezspire |
| La Jolla Pharmaceutical Company | $27.74 | 2022 | |
| Abbvie INC. | $26.74 | 2021-2022 | |
| Csl Behring | $23.00 | 2019 | |
| Bioxcel Therapeutics, INC. | $18.71 | 2023 | Igalmi |
| Mallinckrodt Enterprises LLC | $15.66 | 2019 | |
| Allergan, INC. | $15.11 | 2020 | |
| Lilly USA, LLC | $14.71 | 2025 | Zepbound |
| Inogen, INC. | $14.61 | 2022 | |
| Viatris Specialty LLC | $14.47 | 2025 | Yupelri |
| Boston Scientific Corporation | $12.62 | 2022 | |
| Gilead Sciences, INC. | $11.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Wilds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.